待债券发行完成后，公司拟将发行债券的所得款项净额用作：(1)提升公司国内及国际研发能力以及一 站式解决方案提供能力；(2)提升国内及国际商业化能力，并扩大业务发展及营销团队；(3)透过兴建厂 房扩大国内及国际交付及研发能力；及(iv)营运资金和一般公司用途。 格隆汇1月8日丨晶泰控股(02228.HK)发布公告，2026年1月7日，公司与经办人(即摩根大通、高盛及 BofA SECURITIES)签署认购协议，据此，公司已同意发行本金总额为28.66亿港元的债券(即公司28.66 亿港元于2027年到期的零息可换股债券)，而经办人已个别(而非共同)同意认购并支付或促使认购人认购 并支付该等债券的款项，惟须受认购协议所载若干条件规限。 假设按初始转换价每股股份13.85港元悉数转换债券，则债券将转换为约2.07亿股股份，相当于公司于本 公告日期已发行股本总额的约4.81%，及悉数转换债券后的经扩大已发行股本总额的约4.59%。转换股 份将根据一般授权予以配发及发行。 ...

Group 1 - The company has entered into a subscription agreement with Fucai Holdings to issue convertible bonds totaling $35 million (approximately HKD 272.3 million) [1] - The initial conversion price is set at HKD 0.66 per share, which could lead to the issuance of up to 412.6 million shares, representing approximately 42.28% of the total shares currently issued [1] - If the conversion rights are fully exercised, the total issued share capital will increase by approximately 29.72%, assuming no changes in the company's issued capital from the announcement date until conversion [1] Group 2 - The board believes that the subscription will strengthen the company's capital base and prepare for long-term development and improved financial status [2] - Issuing convertible bonds will not cause immediate dilution of existing shareholders' equity [2] - The company sees the issuance of convertible bonds as an opportunity to expand and strengthen its capital base while attracting new investors to broaden its shareholder base [2]

Core Viewpoint - China Biotechnology Services (08037) has entered into a subscription agreement with Fucai Holdings to issue convertible bonds worth $35 million, equivalent to approximately HKD 272.3 million, aimed at strengthening the company's capital base and financial position [1] Group 1: Convertible Bonds Issuance - The company has conditionally agreed to issue convertible bonds with a principal amount of $35 million [1] - The initial conversion price is set at HKD 0.66 per share, which is subject to adjustment [1] - If the conversion rights attached to the bonds are fully exercised, up to 412.6 million shares will be issued, representing approximately 42.28% of the total shares currently in issue [1] Group 2: Impact on Shareholders - The issuance of convertible bonds will not cause immediate dilution of existing shareholders' equity [1] - If the conversion rights are exercised, the total number of shares issued will increase by approximately 29.72%, assuming no changes in the company's issued share capital from the announcement date until conversion [1] Group 3: Investor Profile - The subscriber, Fucai Holdings, primarily engages in investment activities across various sectors, including life sciences, education, internet, technology media, and telecommunications, managing assets exceeding $100 million [1] Group 4: Strategic Rationale - The board believes that the subscription will enhance the company's capital foundation, preparing for long-term development and improving financial conditions [1] - The issuance of convertible bonds is seen as an opportunity to expand and strengthen the capital base while attracting new investors to broaden the shareholder base [1]

Core Viewpoint - China Biotechnology Services (08037.HK) has entered into a subscription agreement with Fucheng Holdings Limited for the issuance of convertible bonds totaling $35 million, equivalent to approximately HKD 272.3 million, with a conversion price set at HKD 0.66 per share, representing a discount of about 16.46% from the closing price of HKD 0.79 on the agreement date [1] Group 1 - The total principal amount of the convertible bonds is $35 million, which will result in a maximum issuance of approximately 413 million shares, accounting for about 42.28% of the total shares outstanding as of the announcement date [1] - The net proceeds from the issuance of the convertible bonds are expected to be approximately $33.9 million [1] - The company plans to allocate 47.6% of the net proceeds for repaying other loans' principal and interest [1] Group 2 - 25.8% of the net proceeds will be used for the development and construction of a network of boron neutron capture therapy centers for cancer treatment [1] - 5.7% of the net proceeds will be allocated for research and development costs [1] - 20.9% of the net proceeds will be utilized for general working capital purposes [1]

尚太科技公告，近日收到中国证券监督管理委员会出具的《关于同意石家庄尚太科技股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2025〕2788号），同意公司向不特定对象发行 可转换公司债券的注册申请。本次发行应严格按照报送深圳证券交易所的申报文件和发行方案实施。本 批复自同意注册之日起12个月内有效。 ...

中汽股份公告，公司于2025年12月10日收到深圳证券交易所出具的《关于受理中汽研汽车试验场股份有 限公司向不特定对象发行可转换公司债券申请文件的通知》。深交所对公司报送的向不特定对象发行可 转换公司债券的申请文件进行了核对，认为申请文件齐备，决定予以受理。公司本次向不特定对象发行 可转换公司债券事项尚需深交所审核，并获得中国证券监督管理委员会作出同意注册的决定后方可实 施。 ...

Core Viewpoint - CleanSpark plans to raise $1 billion through the issuance of zero-coupon convertible bonds to support its ongoing business expansion, despite experiencing a significant stock price decline of over 36% from its October peak [1] Group 1: Company Actions - The company intends to issue zero-coupon convertible bonds maturing in 2032 [1] - Up to $400 million of the raised funds will be allocated for stock buybacks [1] - Remaining funds will be used for expanding its power and land asset portfolio, building data center infrastructure, and debt repayment [1] Group 2: Market Reaction - CleanSpark's stock opened down over 8%, currently trading at $13.84 [1] - The stock has seen a significant decline of more than 36% from its high point in October [1]

Core Viewpoint - Shenyu Co., Ltd. has received approval from the Shenzhen Stock Exchange's Listing Review Committee for its application to issue convertible bonds to unspecified investors, pending registration with the China Securities Regulatory Commission (CSRC) [1][2]. Group 1: Convertible Bond Issuance - The company plans to raise a total of up to RMB 50 million through the issuance of convertible bonds, which will be fully allocated to the smart field data line construction project [1][2]. - The convertible bonds will have a term of six years from the date of issuance and will be convertible into the company's A-shares listed on the Shenzhen Stock Exchange [2][3]. Group 2: Shareholding Structure - As of the signing date of the fundraising prospectus, Ren Fengjuan holds 36,110,800 shares, accounting for 20.13% of the total shares, making her the controlling shareholder [3][4]. - The combined shareholding of Ren Fengjuan, her daughter Tang Xiaonan, and her husband Tang Jiankang amounts to 39.65% of the total shares, indicating significant influence over company decisions [3][4]. Group 3: Underwriting and Sponsorship - The lead underwriter for this bond issuance is Huatai United Securities Co., Ltd., with representatives Lü Fuxing and Li Jun overseeing the sponsorship [4].

证券代码：300378 证券简称：鼎捷数智 鼎捷数智股份有限公司 向不特定对象发行可转换公司债券预案 （二次修订稿） 二〇二五年八月 公司声明 在虚假记载、误导性陈述或重大遗漏，并对本预案内容的真实性、准确性、完整 性承担个别和连带的法律责任。 由公司自行负责；因本次向不特定对象发行可转换公司债券引致的投资风险，由 投资者自行负责。 任何与之相反的声明均属不实陈述。 其他专业顾问。 转换公司债券相关事项的实质性判断、确认、批准或核准。本预案所述本次向不 特定对象发行可转换公司债券相关事项的生效和完成尚待深圳证券交易所审核 通过，并经中国证监会同意注册。 资者或相关人士的承诺，投资者及相关人士应当理解计划、预测或承诺之间的差 异，并注意投资风险。 释义 本预案中除另有说明外，下列简称具有如下含义： 发行人、公司、本公司、 指 鼎捷数智股份有限公司 股份公司、鼎捷数智 鼎捷数智本次拟向不特定对象发行可转换公司债券的 本次发行、本次可转债 指 事项 鼎捷数智本次拟向不特定对象发行的可转换为A股股票 可转债、可转换公司债券 指 的公司债券 《鼎捷数智股份有限公司向不特定对象发行可转换公 本预案 指 司债券预案》 《可 ...

Core Viewpoint - The company has received notification from the Shenzhen Stock Exchange regarding the acceptance of its application for issuing convertible bonds to unspecified investors, indicating a step forward in its financing strategy [1] Group 1 - The company received a notice from the Shenzhen Stock Exchange on August 14, 2025, regarding the acceptance of its application for issuing convertible bonds [1] - The Shenzhen Stock Exchange has verified that the application documents submitted by the company are complete and has decided to accept the application [1] - The issuance of the bonds is subject to further review by the Shenzhen Stock Exchange and requires approval from the China Securities Regulatory Commission before implementation, introducing uncertainty regarding the approval process and timeline [1]